Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Payables (2021 - 2025)

Historic Payables for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $13.3 million.

  • Roivant Sciences' Payables fell 4393.56% to $13.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.3 million, marking a year-over-year decrease of 4393.56%. This contributed to the annual value of $23.7 million for FY2025, which is 6887.16% up from last year.
  • As of Q4 2025, Roivant Sciences' Payables stood at $13.3 million, which was down 4393.56% from $15.1 million recorded in Q3 2025.
  • Roivant Sciences' 5-year Payables high stood at $194.6 million for Q2 2022, and its period low was $11.5 million during Q2 2025.
  • For the 5-year period, Roivant Sciences' Payables averaged around $38.9 million, with its median value being $26.4 million (2024).
  • Its Payables has fluctuated over the past 5 years, first surged by 119617.69% in 2022, then plummeted by 7428.93% in 2023.
  • Roivant Sciences' Payables (Quarter) stood at $24.4 million in 2021, then skyrocketed by 97.06% to $48.0 million in 2022, then fell by 26.61% to $35.2 million in 2023, then tumbled by 32.69% to $23.7 million in 2024, then tumbled by 43.94% to $13.3 million in 2025.
  • Its Payables was $13.3 million in Q4 2025, compared to $15.1 million in Q3 2025 and $11.5 million in Q2 2025.